SCHEMBL23390366

SCHEMBL23390366

Cc1ccc(-c2cc3c(=O)n([C@@H](C)CO)cnc3c(-c3cccc(F)c3)n2)cc1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM5B Q9UGL1 1/20 0.37
ADORA1 P30542 2/20 0.36
MGAM O43451 2/20 0.36
GAA P10253 2/20 0.36
SI P14410 2/20 0.36
MGAM2 Q2M2H8 2/20 0.36
PDE4A P27815 2/20 0.35
PDE4B Q07343 2/20 0.35
PDE4C Q08493 2/20 0.35
PDE4D Q08499 2/20 0.35
CTSA P10619 1/20 0.35
ALDH1A1 P00352 2/20 0.34
CYP1A2 P05177 2/20 0.34
CYP3A4 P08684 2/20 0.34
CLK4 Q9HAZ1 2/20 0.34
TGFBR1 P36897 2/20 0.34
USP2 O75604 1/20 0.34
TSHR P16473 1/20 0.34
AHR P35869 1/20 0.33
NPC1 O15118 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23390369 1.00 KDM5B (0.37) KDM5BADORA1MGAMGAASI
SCHEMBL26275433 0.92 PIK3CA (0.41) KDM5BADORA1PDE4APDE4BPDE4C
SCHEMBL23390464 0.92 AHR (0.42) KDM5BADORA1PDE4APDE4BPDE4C
SCHEMBL23390466 0.92 AHR (0.42) KDM5BADORA1PDE4APDE4BPDE4C
SCHEMBL29611147 0.92 AHR (0.42) KDM5BADORA1PDE4APDE4BPDE4C
SCHEMBL26275548 0.90 MET (0.39) KDM5BADORA1PDE4APDE4BPDE4C
SCHEMBL26275406 0.88 TGFBR1 (0.35) TGFBR1PIK3CAMTOR
SCHEMBL30232734 0.88 AHR (0.39) KDM5BADORA1PDE4APDE4BPDE4C
SCHEMBL23390382 0.88 AHR (0.39) KDM5BADORA1PDE4APDE4BPDE4C
SCHEMBL23390384 0.88 AHR (0.39) KDM5BADORA1PDE4APDE4BPDE4C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115397512-B As AHR antagonists Pyridopyrimidinone derivatives 先达生物科技公司 2024-12-17 CN claimed
US-20230295152-A1 PYRIDOPYRIMIDINONE DERIVATIVES AS AHR ANTAGONISTS SENDA BIOSCIENCES, INC. (US) 2023-09-21 US claimed
CN-115397512-A Pyridopyrimidinone derivatives as AHR antagonists 先达生物科技公司 2022-11-25 CN claimed
EP-4061484-A1 PYRIDOPYRIMIDINONE DERIVATIVES AS AHR ANTAGONISTS Senda Biosciences, Inc. (US) 2022-09-28 EP claimed
WO-2021102288-A1 PYRIDOPYRIMIDINONE DERIVATIVES AS AHR ANTAGONISTS SENDA BIOSCIENCES, INC. (US) 2021-05-27 WO claimed
CN-115397512-B As AHR antagonists Pyridopyrimidinone derivatives 先达生物科技公司 2024-12-17 CN disclosed
US-20230381182-A1 Biomarkers Related to Immune Checkpoint Inhibitor Therapy and Methods of Using the Same SAIL BIOMEDICINES, INC. 2023-11-30 US disclosed
US-20230381182-A1 Biomarkers Related to Immune Checkpoint Inhibitor Therapy and Methods of Using the Same SAIL BIOMEDICINES, INC. 2023-11-30 US disclosed
US-20230381182-A1 Biomarkers Related to Immune Checkpoint Inhibitor Therapy and Methods of Using the Same SAIL BIOMEDICINES, INC. 2023-11-30 US disclosed
US-20230295152-A1 PYRIDOPYRIMIDINONE DERIVATIVES AS AHR ANTAGONISTS SENDA BIOSCIENCES, INC. (US) 2023-09-21 US disclosed
US-20230295152-A1 PYRIDOPYRIMIDINONE DERIVATIVES AS AHR ANTAGONISTS SENDA BIOSCIENCES, INC. (US) 2023-09-21 US disclosed
US-20230295152-A1 PYRIDOPYRIMIDINONE DERIVATIVES AS AHR ANTAGONISTS SENDA BIOSCIENCES, INC. (US) 2023-09-21 US disclosed
CN-116745622-A Biomarkers related to immune checkpoint inhibitor therapies and methods of use thereof 先达生物科技公司 2023-09-12 CN disclosed
EP-4228649-A1 BIOMARKERS RELATED TO IMMUNE CHECKPOINT INHIBITOR THERAPY AND METHODS OF USING THE SAME Senda Biosciences, Inc. (US) 2023-08-23 EP disclosed
CN-115397512-A Pyridopyrimidinone derivatives as AHR antagonists 先达生物科技公司 2022-11-25 CN disclosed
EP-4061484-A1 PYRIDOPYRIMIDINONE DERIVATIVES AS AHR ANTAGONISTS Senda Biosciences, Inc. (US) 2022-09-28 EP disclosed
WO-2022081649-A1 BIOMARKERS RELATED TO IMMUNE CHECKPOINT INHIBITOR THERAPY AND METHODS OF USING THE SAME SENDA BIOSCIENCES, INC. (US) 2022-04-21 WO disclosed
WO-2022081649-A1 BIOMARKERS RELATED TO IMMUNE CHECKPOINT INHIBITOR THERAPY AND METHODS OF USING THE SAME SENDA BIOSCIENCES, INC. (US) 2022-04-21 WO disclosed
WO-2021102288-A1 PYRIDOPYRIMIDINONE DERIVATIVES AS AHR ANTAGONISTS SENDA BIOSCIENCES, INC. (US) 2021-05-27 WO disclosed
WO-2021102288-A1 PYRIDOPYRIMIDINONE DERIVATIVES AS AHR ANTAGONISTS SENDA BIOSCIENCES, INC. (US) 2021-05-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230295152-A1 PYRIDOPYRIMIDINONE DERIVATIVES AS AHR ANTAGONISTS AHR, ARNT, AIPL1 KDM5B 786/4885ADORA1 382/4885MGAM 4831/4885
US-20230381182-A1 Biomarkers Related to Immune Checkpoint Inhibitor Therapy and Methods of Using the Same AHR, CD274, ARNT KDM5B 643/4885ADORA1 781/4885MGAM 4495/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.